ArticleJMIR research protocols2025
"PrevenganT2," a Culturally Responsive Family-Based Diabetes Prevention Intervention for Hispanic or Latino Adults at High Risk for Type 2 Diabetes: Protocol for a Proof-of-Concept Evaluation.
Article in JMIR research protocols, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundDespite the efficacy of lifestyle interventions for preventing or delaying diabetes, community translations to date have failed to engage Hispanic or Latino participants effectively. Previously identified barriers to engagement include lack of family support and the burden of time-intensive year-long programs. Integrating family members and reducing program length may have the potential to increase engagement in lifestyle interventions to prevent type 2 diabetes in Hispanic or Latino individuals.
objectiveGiven the potential impact of cultural adaptation on such interventions, our community-academic research team used the Obesity-Related Behavioral Intervention Trials (ORBIT) model to guide an adaptation of the core 16 modules of the National Diabetes Prevention Program's PrevengaT2 curriculum to meet the needs of Hispanic or Latino communities in Utah. We describe our evaluation of this adaptation in an ongoing proof-of-concept trial. We will evaluate whether Hispanic or Latino participants at high risk for type 2 diabetes increase their weekly moderate-to-vigorous physical activity (MVPA) in the context of an ongoing proof-of-concept trial of the adaptation.
methodsTarget participants at risk for type 2 diabetes and a family member were invited to participate in PrevenganT2. In earlier phases of a larger project, our academic-community research team created the 14-week lifestyle intervention by adapting the Centers for Disease Control and Prevention's PrevengaT2 curriculum. Objective MVPA was measured for 7 days at preintervention and postintervention using ActiGraph GT3X-BT accelerometers. Participants additionally completed questionnaires at preintervention and postintervention, and weight and self-reported MVPA were recorded at lifestyle intervention classes. Physical activity data will be analyzed to determine the percentage of target participants with clinically significant pre-post increases in MVPA.
resultsData collection concluded in October 2024. Data cleaning and preparation for analysis are ongoing. We expect that results will be submitted for publication by June 2025.
conclusionsThis study serves as a first step in evaluating a novel, culturally adapted lifestyle intervention to prevent type 2 diabetes in Hispanic or Latino adults. Although this small study is not without limitations, findings will inform our team's next steps for this early-phase intervention work. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/66317.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.